Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
The Ras Gene02:38

The Ras Gene

6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concurrent Chemoradiotherapy Plus Immunotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer: A Randomized, Single-Center, Phase II Trial of Early Tumor Regression and Pro-Inflammatory Tumor Microenvironment Remodeling.

MedComm·2026
Same author

Identification of a master regulator Msd1 that governs meiotic entry in a global basidiomycete pathogen.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

STAT2-IRF1-ISG15-Associated Temporal Immune Reprogramming in Macrophages during Aspergillus fumigatus Infection.

Current microbiology·2026
Same author

Predictive value of ALBI score in assessing prognosis of NSTEMI: a retrospective cohort study.

Frontiers in cardiovascular medicine·2026
Same author

Study on the characteristics of W<sub>1</sub>/O/W<sub>2</sub> emulsion delivery system stabilized by soybean protein isolate/(-)-epigallocatechin gallate/exopolysaccharides complex.

Food research international (Ottawa, Ont.)·2026
Same author

From Analysis to Assessment: Machine Learning for Non-Target Screening of Pollutants Using Chromatography Coupled with (Ion Mobility) Mass Spectrometry.

Toxics·2026

Related Experiment Video

Updated: Jun 16, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

8.6K

EGFR mutations and abnormal trafficking in cancers.

Xiang Kang1,2, Rendong Li1,2, Xiaolei Li2,3

  • 1The First Clinical Medical College, Nanchang University, Nanchang, 30006, China.

Molecular Biology Reports
|August 21, 2024
PubMed
Summary

Epidermal growth factor receptor (EGFR) drives cancer through mutations and overexpression. This review covers EGFR

Keywords:
DegradationEGFREGFR traffickingMalignant tumorsMutationRegulation

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Related Experiment Videos

Last Updated: Jun 16, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

8.6K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Epidermal growth factor receptor (EGFR) is a key transmembrane tyrosine kinase in the ErbB family.
  • Aberrant EGFR expression, including mutations and overexpression, is linked to tumorigenesis in various cancers.

Purpose of the Study:

  • To review the aberrant expression of EGFR in common cancers.
  • To summarize current therapeutic strategies targeting EGFR.
  • To compare EGFR trafficking in normal versus cancer cells and identify regulatory factors.

Main Methods:

  • Literature review of EGFR expression, cancer association, and therapeutic strategies.
  • Comparative analysis of EGFR activation, internalization, endocytosis, and sorting mechanisms.
  • Identification of regulatory factors influencing EGFR trafficking.

Main Results:

  • EGFR is frequently overexpressed or mutated in many cancers, correlating with disease progression.
  • Various therapeutic strategies targeting EGFR have been developed.
  • Significant differences exist in EGFR trafficking pathways between normal and cancer cells.

Conclusions:

  • EGFR is a critical target in cancer therapy due to its role in tumorigenesis.
  • Understanding EGFR trafficking is crucial for developing effective cancer treatments.
  • Further research into EGFR regulatory factors may yield novel therapeutic approaches.